The Netherlands
Avidicure, founded in 2022, is pioneering the development of antibody therapies it calls "Actibodies," aimed at providing innovative solutions in immune-modulating treatments for cancer and auto-immune diseases. By forging a new class of potent therapies, Avidicure addresses critical needs in the healthcare industry.
The company recently secured a significant €43.97M seed investment on 01 April 2025. This infusion of capital reflects the strong interest from prominent investors, including Kurma Partners, BioGeneration Ventures, Curie Capital, V-Bio Ventures, EQT Life Sciences, and BOM - Brabant Regional Development Agency. These backers recognize the potential impact of Avidicure's Actibodies on the medical landscape.
Despite its brief operating history, Avidicure is positioned as a forward-thinking entity in the biopharmaceutical sector. Its bold approach in developing first-in-class products is complemented by substantial investor confidence, laying a foundation for potential growth and successful commercialization in the future.
